![Lineage Cell Therapeutics, Inc. logo](/logos/LCTX.webp)
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
Overview | Financials
Company Name | Lineage Cell Therapeutics, Inc. |
Symbol | LCTX |
Currency | USD |
Price | 0.95 |
Market Cap | 166,237,658 |
Dividend Yield | 0% |
52-week-range | 0.93 - 1.58 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Brian M. Culley M.A., M.B.A. |
Website | https://www.lineagecell.com |
An error occurred while fetching data.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD